Clinical Trial Update: The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update indicates that CB-Exo-A600 is being studied for mild to moderate Alzheimer's disease in Phase 1/2 and is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CB-Exo-A600 (CB-Exo-A600)

Snippet

Sponsor: Xuanwu Hospital, Beijing | Conditions: Mild to Moderate Alzheimer's Disease | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING